Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Authors:

Abstract
Background: 131 I‐metaiodobenzylguanidine ( 131 I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment. However, response rates to 131 I‐MIBG in the anti‐GD2 era are unknown, and the factors associated with response are poorly defined. Procedure: We retrospectively quantified objective response rates (ORR) to 131 I‐MIBG and evaluated the association between clinical and molecular features—including receipt of anti‐GD2 immunotherapy—and ORR among participants with R/R NB from 2011 to 2023. Variables with an unadjusted odds ratio [uOR] p  < 0.2 in a univariable screen were included in multivariable analysis. Results: A total of 125 participants with relapsed (60.8%) or refractory (39.2%) NB were included. Fifty‐eight (46.4%) previously received anti‐GD2 antibody therapy. Forty‐seven (37.6%) achieved an objective response to 131 I‐MIBG therapy, 56 had stable disease (SD; 44.8%), and 22 had progressive disease (17.6%). Compared to immunotherapy‐naïve participants (ORR 35.8%), participants who previously received anti‐GD2 therapy (39.7%, uOR 1.18 [0.57–2.4]) and specifically chemoimmunotherapy (37.5%, 0.99 [0.42–2.26]) had similar rates of response to 131 I‐MIBG. Asians compared to Whites (adjusted OR 0.21 [0.05–0.95]), no bone marrow disease (0.17 [0.06–0.50]), and higher Curie score (0.90 [0.83–0.98]) were significantly associated with lower odds of response. Conclusion: Prior exposure to anti‐GD2 therapy was not associated with differential response to 131 I‐MIBG. ORR in this modern cohort was comparable to that reported in previous studies. Participants with bone marrow disease and a lower Curie score have a significantly higher ORR to 131 I‐MIBG therapy.

This publication has 15 references indexed in Scilit: